VR Logo

Virios Therapeutics Inc. (VIRI) download report


Healthcare | Biotechnology & Pharma Research

Virios Therapeutics Inc. (VIRI) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.

IPO Date: 17-Dec-2020

Chairman & CEO: Mr. Greg Duncan

Sr. VP of Operations: Mr. Ralph D. Grosswald M.P.H.

Listing: NASDAQ: VIRI

Country: United States

Headquarters: Alpharetta, GA

Website: https://www.virios.com

Key Facts

Market cap: $35.65 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-16.86 Mln

Cash: $11.35 Mln

Total Debt: $0.00 Mln

Insider's Holding: 11.20%

Liquidity: Low

52 Week range: $3.20 - 7.21

Shares outstanding: 8,330,390

Stock Performance

Time Period Virios Therapeutics (VIRI) S&P BSE Sensex* S&P Small-Cap 600*
YTD-14.17-8.71-16.64
1 month4.77-3.11-6.45
3 months-18.40-7.30-12.22
1 Year-33.380.48-15.87
3 Years--10.347.51
5 Years--11.436.63
10 Years--12.1010.46
As on 27-Jun-2022 *As on 28-Jun-2022
Year Virios Therapeutics (VIRI) S&P Small-Cap 600 S&P BSE Sensex
2021-31.8925.2721.99